DeuteRx is involved in improving medicines for patients. This description is self-described.

DeuteRx

DeuteRx | 254 followers on LinkedIn. Devoted to improving patients&#39; lives and advancing small molecule therapies through Deuterium-Enriched Chiral Switching. | Formed in 2012, DeuteRx is a virtual biopharmaceutical company focused on improving racemic drugs for patients. Our team has pioneered the use of Deuterium-Enabled Chiral Switching (DECS) to isolate a single stereoisomer from a mixture of interconverting stereoisomers. 

DECS is a revolutionary strategy that stabilizes the preferred stereoisomer in existing drugs sold as racemic mixtures to reduce deleterious side-effects and improve efficacy.

Life Sciences Executive & Serial Entrepreneur

Sheila DeWitt, PhD

Life Sciences CEO | Specializing in Early-stage Companies

Mike Webb

Founder, President, Chairman & CSO at RIFFIT

Lex Van Der Ploeg

Check out the results of our collaborative research effort with POXEL ! #PXL065 is the deuterium-stabilized (R)-enantiomer of pioglitazone and may be a safer and more effective NASH treatment than racemic pioglitazone. #NASH #NonAlcoholicSteatohepatitis #drugdiscovery #drugdevelopment #liverhealth #liverdisease #pioglitazone #DECS #DeuteriumEnabledChiralSwitching #DeuteRx #deuterium #racemic #enantiomer #innovationinhealthcare

DEUT

COM:DEUTERX

DeuteRx